Lantern Pharma Inc. (NASDAQ: LTRN) was founded in 2013 and is headquartered in Dallas, Texas, with 7 full-time employees. It is a clinical-stage biotechnology company dedicated to the use of artificial intelligence (AI), machine learning and genomic data to simplify medicine Develop the process and identify patients who will benefit from the company’s targeted tumor therapy.
Lantern Pharma Inc. (LTRN):
Lantern Pharma is an emerging, clinical-stage pharmaceutical company focused on oncology, located at the intersection of artificial intelligence, genomics and machine learning. The company’s mission is to provide cancer patients with precise tumor treatments while drastically reducing time and economic costs. Lantern authorizes the use of genomic data, machine learning, and computational biology models to license and develop therapies to identify the group of patients most likely to respond to the therapy and to elucidate the underlying mechanisms of action.
Lantern Pharma, Inc.’s therapeutic portfolio includes small molecules that others have tried but failed to develop into approved commercial drugs, and new compounds developed by the company with the assistance of AI and biomarker-driven methods.
Lantern Pharma’s artificial intelligence platform is called-RADR®, which currently includes more than 275 million data points and uses big data analysis (combined molecular data, drug efficacy data, historical research data, scientific literature data, trials and publications Phenotypic data and mechanism pathway data) and machine learning to quickly discover biologically relevant genomic features related to drug response, and then identify cancer patients that the company believes may benefit the most from its drugs.
Lantern Pharma Inc. (LTRN) financing:
- On August 28, 2014, the seed round received a $30,000 investment from Health Wildcatters.
- On February 26, 2015, Green Park & Golf Ventures received USD 1 million investment.
- On March 4, 2015, it received an investment of 800,000 US dollars.
- On May 2, 2017, A round of financing received US$3.7 million from two institutions, Bios Partners and GPG Ventures.
- On March 18, 2019, the amount and investors of the new round of financing were not disclosed.
Lantern Pharma Inc. (LTRN) investment:
Lantern Pharma Inc. (NASDAQ: LTRN) listed on NASDAQ on June 11, 2020, with an issue price of $15.00. It issued 1.6 million shares and raised $24 million. ThinkEquity (a division of Fordham Financial Management) underwritten.